An open label multi facilities cooperation randomized control trial to verify renoprotective effects of pioglitazone therapy in diabetic nephropathy
Not Applicable
- Conditions
- Type 2 diabetic nephropathy patients with chronic kidney disease (CKD)
- Registration Number
- JPRN-UMIN000001126
- Lead Sponsor
- Graduate School of Medicine, Tohoku University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1) A serum creatinine (Cr) level is more than 2.5 (mg/dl) and existence of hematuria.2) Patient who has received continuous dialysis.3) Severe diabetic complications such as retinal hemorrhage, neuropathy, and so on.4) Existence of severe hepatic damages, and cerebrovascular disorders including heart failure.5) Severe hypertension (BP>160/110 mmHg)6) Patients who judged that physician in charge is improper.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method